A Phase 1, 2-Part, Open-label Study to Evaluate Relative Bioavailability of Alternate Formulations of BMS-986460 in Healthy Adult Male Participants (Part 1), and a Single Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of BMS-986460 in Healthy Adult Male Participants (Part 2)
Latest Information Update: 17 Apr 2025
At a glance
- Drugs BMS 986460 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 13 Apr 2025 Status changed from not yet recruiting to recruiting.
- 20 Mar 2025 New trial record